1. Home
  2. TPCS vs IGC Comparison

TPCS vs IGC Comparison

Compare TPCS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • IGC
  • Stock Information
  • Founded
  • TPCS 1956
  • IGC 2005
  • Country
  • TPCS United States
  • IGC United States
  • Employees
  • TPCS N/A
  • IGC N/A
  • Industry
  • TPCS Metal Fabrications
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • TPCS Industrials
  • IGC Health Care
  • Exchange
  • TPCS Nasdaq
  • IGC Nasdaq
  • Market Cap
  • TPCS 32.1M
  • IGC 29.4M
  • IPO Year
  • TPCS N/A
  • IGC N/A
  • Fundamental
  • Price
  • TPCS $3.48
  • IGC $0.36
  • Analyst Decision
  • TPCS
  • IGC Strong Buy
  • Analyst Count
  • TPCS 0
  • IGC 2
  • Target Price
  • TPCS N/A
  • IGC $3.75
  • AVG Volume (30 Days)
  • TPCS 28.9K
  • IGC 441.4K
  • Earning Date
  • TPCS 02-27-2025
  • IGC 02-12-2025
  • Dividend Yield
  • TPCS N/A
  • IGC N/A
  • EPS Growth
  • TPCS N/A
  • IGC N/A
  • EPS
  • TPCS N/A
  • IGC N/A
  • Revenue
  • TPCS $32,205,714.00
  • IGC $1,183,000.00
  • Revenue This Year
  • TPCS N/A
  • IGC N/A
  • Revenue Next Year
  • TPCS N/A
  • IGC $13.57
  • P/E Ratio
  • TPCS N/A
  • IGC N/A
  • Revenue Growth
  • TPCS 1.51
  • IGC N/A
  • 52 Week Low
  • TPCS $2.85
  • IGC $0.27
  • 52 Week High
  • TPCS $5.95
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 44.90
  • IGC 45.97
  • Support Level
  • TPCS $3.61
  • IGC $0.33
  • Resistance Level
  • TPCS $3.94
  • IGC $0.39
  • Average True Range (ATR)
  • TPCS 0.26
  • IGC 0.03
  • MACD
  • TPCS -0.02
  • IGC -0.00
  • Stochastic Oscillator
  • TPCS 33.33
  • IGC 33.75

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: